Trial Profile
A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and antiviral effect of current standard antiretroviral therapy compared to once daily integrase inhibitor administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Dolutegravir (Primary) ; Ritonavir (Primary) ; Antiretrovirals; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms PENTA 17 - SMILE; SMILE; SMILE (PENTA 17)
- 11 Dec 2023 Results from PK substudy, assessing pharmacokinetics of DRV in the younger population and the importance of the RTV boosting effect, published in the Antimicrobial Agents and Chemotherapy
- 30 Sep 2020 Status changed from active, no longer recruiting to completed.
- 04 Mar 2020 This trial has been completed in Germany, according to European Clinical Trials Database.